Identification of a novel cytotoxic T lymphocyte epitope from CFP21, a secreted protein of Mycobacterium tuberculosis

Immunology Letters

Volumn 133, Issue 2, 2010, Pages 94-98

  Lv, Hong ^a   Gao, Yanfeng ^a   Wu, Yahong ^a   Zhai, Mingxia ^a   Li, Lu ^a   Zhu, Yuhuang ^a   Liu, Wei ^a   Wu, Zongyin ^a   Chen, Fei ^a   Qi, Yuanming ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

CFP21; Cytotoxic T lymphocytes; Epitope; Mycobacterium tuberculosis

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; GAMMA INTERFERON; GENE PRODUCT; HLA A ANTIGEN; PROTEIN CFP21; PROTEIN P134; PROTEIN P134 1Y2L; PROTEIN P134 1Y2L9L; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; MYCOBACTERIUM TUBERCULOSIS; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN SECRETION; PROTEIN STABILITY;

ANTIGENS, BACTERIAL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE FRAGMENTS; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; TUBERCULOSIS; VACCINES, SUBUNIT;

EID: 77956995239     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.07.007     Document Type: Article

References (36)

1. De Groot A.S., McMurry J., Marcon L., Franco J., Rivera D., Kutzler M., et al. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 2005, 23:2121-2131.
2. Sable S.B., Kalra M., Verma I., Khuller G.K. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol 2007, 122:239-251.
3. Doherty T.M., Andersen P. Vaccines for tuberculosis: novel concepts and recent progress. Clin Microbiol Rev 2005, 18:687-702.
4. Kaufmann S.H. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007, 5:491-503.
5. + T cells to control of Mycobacterium tuberculosis infection. J Immunol 2006, 176:4296-4314.
6. + T cells and the development of central memory during Mycobacterium tuberculosis infection. J Immunol 2006, 177:6361-6369.
7. Carlisle J., Evans W., Hajizadeh R., Nadaf M., Shepherd B., Ott R.D., et al. Multiple Mycobacterium antigens induce interferon-γ production from sarcoidosis peripheral blood mononuclear cells. Clin Exp Immunol 2007, 150:460-468.
8. Chaitra M.G., Shaila M.S., Chandra N.R., Nayak R. HLA-A0201-restricted cytotoxic T-cell epitopes in three PE/PPE family proteins of Mycobacterium tuberculosis. Scand J Immunol 2008, 67:411-417.
9. Blythe M.J., Zhang Q., Vaughan K., de Castro R., Salimi N., Bui H.H., et al. An analysis of the epitope knowledge related to Mycobacteria. Immunol Res 2007, 3:10-22.
10. +T cells in HLA-transgenic mice and humans. J Immunol 2000, 165:6463-6471.
11. Aoshi T., Nagata T., Suzuki M., Hashimoto D., Rafiei A., Suda T., et al. Identification of an HLA-A0201-restricted T-cell epitope on the MPT51 protein, a major secreted protein derived from Mycobacterium tuberculosis, by MPT51 overlapping peptide screening. Infect Immun 2008, 76:1565-1571.
12. b-restricted T-cell epitopes on a novel protective antigen, MPT51, of Mycobacterium tuberculosis. Infect Immun 2004, 72:3829-3837.
13. + T cells recognize epitopes of the 28-kDa hemolysin and the 38-kDa antigen of Mycobacterium tuberculosis. J Leukoc Biol 2003, 74:1008-1014.
14. Grover A., Ahmed M.F., Verma I., Sharma P., Khuller G.K. Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model. Protein Expr Purif 2006, 48:274-280.
15. Hovav A.H., Fishman Y., Bercovier H. Gamma interferon and monophosphory lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine. Infect Immun 2005, 73:250-257.
16. Sable1 S.B., Kalra M., Verma I., Khuller G.K. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity. Clin Immunol 2007, 122:239-251.
17. + T-cell epitopes. Cell Mol Immunol 2009, 6:97-103.
18. Mommaas B., Kamp J., Drijfhout J.W., Beekman N., Ossendorp F., van Veelen P., et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 2002, 169:3131-3136.
19. Keşmir C., Nussbaum A.K., Schild A.K., Detours V., Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 2002, 15:287-296.
20. Tourdot S., Scardino A., Saloustrou E., Gross D.A., Pascolo S., Cordopatis P., et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 2000, 30:3411-3421.
21. Ruppert J., Sidney J., Celis E., Kubo R.E., Grey H.M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993, 74:929-937.
22. Lazoura E., Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem 2005, 12:629-639.
23. + T cell epitope from over-expressed antigen COX-2 in esophageal carcinoma. Cancer Lett 2009, 284:55-61.
24. Tang Y., Lin Z.H., Ni B., Wei J., Han J.F., Wang H.M., et al. An altered peptide ligand for naïve cytotoxic T lymphocyte epitope of TRP-2(180-188) enhanced immunogenicity. Cancer Immunol Immunother 2007, 56:319-329.
25. Li F., Yang D., Wang Y.Q., Liu B.H., Deng Y.J., Wang L., et al. Identification and modification of an HLA-A0201-restricted cytotoxic T lymphocyte epitope from Ran antigen. Cancer Immunol Immunother 2009, 58:2039-2049.
26. He Y.D., Mao L.W., Lin Z.H., Deng Y.J., Tang Y., Jiang M., et al. Identification of a common HLA-A0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy. Mol Immunol 2008, 25:2455-2464.
27. Boss C.N., Grünebach F., Brauer K., Häntschel M., Mirakaj V., Weinschenk T., et al. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res 2007, 13:3347-3355.
28. Tanaka F., Fujie T., Go H., Baba K., Mori M., Takesako K., et al. Efficient induction of antitumor cytoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol Immunother 1997, 44:21-26.
29. Vertuani S., Sette A., Sidney J., Southwood S., Fikes J., Keogh E., et al. Improved immunogenicity of an immunodominant epitope of the Her-2/neu protooncogene by alterations of MHC contact residues. J Immunol 2004, 172:3501-3518.
30. Ding F.X., Wang F., Lu Y.M., Li K., Wang K.H., He X.W., et al. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009, 49:1492-1502.
31. Gupta U.D., Katoch V.M., McMurry D.N. Current status of TB vaccines. Vaccine 2007, 25:3742-3751.
32. Van den Eynde B.J., van der Bruggent P. T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693.
33. Kessler J.H., Melief C.J.M. Identification of T-cell epitopes for cancer Immunotherapy. Leukemia 2007, 21:1859-1874.
34. McMurry J.A., Kimball S., Lee J.H., Rivera D., Martin W., Weiner D.B., et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med 2007, 7:351-363.
35. Tangri S., Ishioka G.Y., Huang X.Q., Sidney J., Southwood S., Fikes J., et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001, 194:833-846.
36. Mehra N.K., Jaini R., Rajalingam R., Balamurugan A., Kaur G. Molecular diversity of HLA-A02 in Asian Indians: predominance of A0211. Tissue Antigens 2001, 57:502-507.